Research comparison
SS-31 vs MOTS-c: origin, mechanism, evidence, and development status
SS-31 and MOTS-c are often paired because both appear in mitochondrial research. Their origins, structures, proposed actions, translational evidence, and regulatory histories are different, so a shared theme should not be mistaken for equivalence.
Educational content only. Not medical advice.
Origin: synthetic targeting versus mitochondrial encoding
SS-31 is a synthetic tetrapeptide developed as elamipretide and designed for mitochondrial membrane targeting. MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. The first is categorized by engineered localization and development history; the second by genomic origin and endogenous signaling research.
This distinction rules out simple substitution. The molecules have different sequences, sources, targets, exposures, and study programs even when both are discussed under the broad theme of mitochondrial function.
Mechanism: membrane context versus stress signaling
SS-31 studies emphasize the inner mitochondrial membrane, cardiolipin-associated organization, energetics, and oxidative processes. MOTS-c studies emphasize metabolic and stress-response signaling across cellular compartments, including reported interactions with nutrient-sensing pathways in preclinical models.
Neither mechanism description is a clinical outcome. A change in membrane behavior, gene expression, or metabolic signaling can support biological plausibility while leaving the size, durability, and safety of a human effect unknown.
Human evidence and regulatory status differ sharply
Elamipretide has indication-specific randomized human trial data and an FDA accelerated-approval history for a narrowly defined Barth syndrome population. The randomized and open-label phases must remain separately interpreted, and the regulator decision cannot be generalized beyond its scope.
MOTS-c's foundational evidence is mainly cellular and animal, with human work more limited and often observational or translational. Endogenous MOTS-c associations do not establish the effects of administered synthetic peptide. The two evidence ladders therefore cannot be compared by counting papers alone.
The comparison that the evidence permits
A defensible table can compare sequence length, origin, proposed research locus, model types, presence of controlled human outcomes, and official development status. It cannot declare a better anti-aging, energy, exercise, or wellness peptide because those shared consumer outcomes have not been established by this source set.
This comparison contains no dose, protocol, administration, reconstitution, procurement, or combination guidance. Its public value is taxonomic: it shows why two mitochondrial research narratives represent different molecules and different levels of evidence.
Evidence limits
- The molecules have no direct head-to-head clinical trial and are not being developed as interchangeable interventions.
- MOTS-c has a predominantly preclinical evidence base, while elamipretide evidence is condition-specific.
- No shared consumer wellness outcome can be ranked from the cited sources.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
Cell Metabolism
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Foundational primary MOTS-c source, based on cellular and mouse models.
Open sourceGenetics in Medicine
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate elamipretide in Barth syndrome
Controlled human elamipretide evidence illustrating the molecule's separate clinical development track.
Open sourceU.S. Food and Drug Administration
FDA Grants Accelerated Approval for First Treatment for Barth Syndrome
Official source for elamipretide's narrow, date-specific regulatory context.
Open sourcePhysiological Reports
The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity
Review of MOTS-c signaling concepts and translational questions.
Open sourceCommon questions
Are SS-31 and MOTS-c both mitochondrial-derived peptides?
No. MOTS-c is encoded within mitochondrial DNA. SS-31 is a synthetic mitochondria-targeted peptide.
Which one has more human clinical evidence?
Elamipretide/SS-31 has indication-specific controlled human trial and regulatory evidence. That does not establish broad wellness benefits or make it comparable to MOTS-c for an untested outcome.
Continue with context
Continue in the PeptideSchool workspace
Use the member workspace to organize references, compare research notes, and explore the complete peptide library. Protocol, dosage, and reconstitution material remains inside the appropriate Premium context.